meta
|
evidence
oncology
Living systematic review and meta-analysis
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - maintenance (M)
2
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
5
Extensive stage SCLC (Es-SCLC) - 2nd line (L2)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
durvalumab based treatment
durvalumab plus etoposide and platin
pembrolizumab based treatment
pembrolizumab plus SoC
Immune checkpoint association
durvalumab plus tremelimumab
durvalumab plus tremelimumab plus SoC
versus all
vs chemotherapy
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs etoposide plus platin
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
Age < 65y (younger)
Age > 65y
Asian type
ECOG 0
ECOG 1
Gender, female
Gender, male
metastasis (brain) NO
metastasis (brain) YES
metastasis (liver )
smoker (current or former)
smoker (Current)
smoker (never)
stage III (locally advanced)
stage IV (metastatic)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
DOR
objective responses (ORR)
progression or deaths (PFS)
AE (any grade)
AE (grade 3-4)
AE leading to death (grade 5)
AE leading to treatment discontinuation (any grade)
STRAE (any grade)
STRAE (grade 3-4)
TRAE (any grade)
TRAE (grade 3-4)
TRAE leading to death (grade 5)
TRAE leading to discontinuation (any grade)
TRAE leading to discontinuation (grade 3-4)
Adrenal insufficiency TRAE (grade 3-4)
Alopecia TRAE (grade 3-4)
Anaemia TRAE (grade 3-4)
Asthenia TRAE (grade 3-4)
Constipation TRAE (grade 3-4)
Decreased appetite TRAE (grade 3-4)
Diabetes TRAE (grade 3-4)
Diarrhoea TRAE (grade 3-4)
Fatigue TRAE (grade 3-4)
Febrile neutropenia TRAE (grade 3-4)
Hyperthyroidism TRAE (grade 3-4)
Hypophysitis TRAE (grade 3-4)
Hypothyroidism TRAE (grade 3-4)
Increased lipase level TRAE (grade 3-4)
Leucopenia TRAE (grade 3-4)
Myocarditis TRAE (grade 3-4)
Nausea TRAE (grade 3-4)
Neutropenia TRAE (grade 3-4)
Paraesthesia TRAE (grade 3-4)
Pneumonitis TRAE (grade 3-4)
Pruritus TRAE (grade 3-4)
Rash TRAE (grade 3-4)
Thrombocytopenia TRAE (grade 3-4)
Thyroiditis TRAE (grade 3-4)
Vomiting TRAE (grade 3-4)
Alopecia AE (grade 3-4)
Anaemia AE (grade 3-4)
Asthenia AE (grade 3-4)
Back pain AE (grade 3-4)
Constipation AE (grade 3-4)
Cough AE (grade 3-4)
Decreased appetite AE (grade 3-4)
Diarrhoea AE (grade 3-4)
Dyspnoea AE (grade 3-4)
Fatigue AE (grade 3-4)
Febrile neutropenia AE (grade 3-4)
Headache AE (grade 3-4)
Hypertension AE (grade 3-4)
Hyperthyroidism AE (grade 3-4)
Increased Lipase Level AE (grade 3-4)
Leucopenia AE (grade 3-4)
Nausea AE (grade 3-4)
Neutropenia AE (grade 3-4)
Pneumonia AE (grade 3-4)
Pruritus AE (grade 3-4)
Pyrexia AE (grade 3-4)
Rash AE (grade 3-4)
Thrombocytopenia AE (grade 3-4)
Vomiting AE (grade 3-4)
deaths (OS)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
versus etoposide plus platin
durvalumab plus tremelimumab plus SoC vs. etoposide plus platin
1
certainty unassessable
-17%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open